Latest Capital Raises News

Zenith Minerals has announced a maiden Inferred Mineral Resource of 675,000 ounces of gold across its Consolidated Dulcie Gold Project in Western Australia, more than doubling previous estimates and setting the stage for accelerated development.

WCM Global Growth Limited has raised approximately $85 million through a share placement and entitlement offer priced at $1.75 per share, aiming to strengthen its global growth investment strategy and enhance shareholder value.

Marimaca Copper has successfully raised C$409 million through a dual Canadian and Australian equity offering, positioning the company to advance its flagship Marimaca Project and exploration at Pampa Medina.

Jameson Resources has marked significant progress in advancing its Crown Mountain steelmaking coal project, doubling its pre-tax NPV to US$942 million and moving closer to final environmental approvals and development permits expected by the end of 2026.

Elevra Lithium reported solid Q2 FY26 production and revenue results while progressing its North American Lithium brownfield expansion and forging strategic supply partnerships.

SkyCity Entertainment Group posted a solid half-year profit increase to NZD 12.1 million despite a slight revenue dip, bolstered by a major equity raise and a clean bill on its Adelaide casino licence.

MEC Resources Ltd reported a half-year loss of $431,971 amid ongoing legal challenges over key gas exploration permits, while progressing investments in clean energy and neurotechnology. The company also completed a $359K options placement, reinforcing its financial position.

AuMEGA Metals has successfully upsized its institutional financing to C$30.1 million, anchored by Condire Investors who will hold nearly 20% of the company. The funds will accelerate exploration programs across its Newfoundland gold projects.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

PhosCo Ltd has raised $5 million through a strongly supported share placement to fund exploration and development at its Gasaat Phosphate Project in Tunisia, positioning the company for upcoming resource milestones.